PRESS RELEASE: IVI Selects Pharmerit to Construct Foundation of Major Depressive Disorder Value Assessment Model
Health Economics Experts to Work with IVI-convened Advisory Group to Assess and Determine Model Inputs October 20, 2020 — Alexandria, VA — The Innovation and Value Initiative (IVI)— a nonprofit organization dedicated to advancing the [...]
IVI MEMBER SPOTLIGHT: Dr. Wayne Burton
For our first Member Spotlight, we chatted with Dr. Wayne Burton about what he sees as the future of value assessment. Dr. Burton has been with IVI almost since its inception. This interview is an [...]
New IVI Member Spotlight Series
We, at the Innovation and Value Initiative, are deeply appreciative and excited about the growing number of members who share our commitment to advancing the science of value assessment. As part of our Value Source [...]
BLOG: Tackling Hard Questions in Value
Author: Jennifer Bright, MPA, Executive Director, IVI For decades, we've known that untreated or poorly treated Major Depressive Disorder (MDD) is an enormous burden on individual patients, our health care system, and our society. Despite [...]
PRESS RELEASE: IVI’s Next Value Assessment Model to Address Major Depressive Disorder Interventions
First of Its Kind Depression Model to be Informed by Input from Diverse Advisory Group September 9, 2020 — Alexandria, VA — The Innovation and Value Initiative (IVI) — a non-profit organization dedicated to advancing [...]
IVI and the University of Maryland Pharmacy School’s PAVE Center Partner on Patient-Centered Value Assessment
In an article in The Patient, IVI and the Patient-Driven Values in Healthcare Evaluation (PAVE) Center at the University of Maryland School of Pharmacy describe how they develop methods and models that make patient-centered value [...]
Second Webinar in the ISPOR-IVI Series Explores Whether Value Assessments are Up to the Task in the Age of COVID-19
The second part of a five-part webinar series examining value assessment in the COVID-19 era hosted by ISPOR and the Innovation and Value Initiative (IVI) will explore whether the methods on which health economists have [...]
BLOG: Exploring Patient Heterogeneity and Diversity in Treatment Responses
Author: Jennifer Bright, MPA Everyone hopes for a COVID vaccine so our lives can return to normal. Yet, we know that even if clinical trials prove a vaccine's effectiveness, our society will still have to [...]
IVI Releases First Annual Report
IVI is pleased to share our Annual Report that documents the transition of our organization to an independent, 501c(3) organization, describes our membership and patient engagement strategies, and offers highlights and learnings from research and [...]
Jennifer Bright Discusses Her Journey and How to Improve Value Assessment
In an interview with Dr. William Seeds in Authority Magazine, Jennifer Bright talks about her own journey to IVI, what drives her to improve value assessment, and why collaboration is paramount for success. Read the [...]
The Promise of MCDA to Improve Equity in Value Assessment
In a commentary in AJMC, IVI examines how multi-criteria decision analysis has the potential to better understand and assess value for innovative cell and gene therapies which are transforming the lives of patients living with [...]
BLOG: How do we identify and measure value for patients with rare diseases?
Authors: Annie Kennedy and Joff Masukawa. Rare diseases impact 1 in 10 Americans, and over 400 million people worldwide. The current development and FDA approval process can cost hundreds of millions of dollars – and [...]